A step towards treating KRAS-mutant NSCLC

被引：8
|
作者：
Goldberg, Sarah B. [1 ,2 ]
Schlessinger, Joseph [1 ,3 ]
Boyer, Julie L. [1 ,2 ]
Herbst, Roy S. [1 ,2 ,3 ]
机构：
[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
来源：
LANCET ONCOLOGY | 2013年 / 14卷 / 01期
关键词：
CELL LUNG-CANCER; DOCETAXEL; TRIAL;
D O I：
10.1016/S1470-2045(12)70528-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：4
相关论文
共 50 条
  • [41] Hope for targeted treatment of KRAS-mutant lung cancer
    Crisp, Alisa
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (02) : 121 - 121
  • [42] Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors
    Zhao, Yulei
    Xue, Jenny Y.
    Lito, Piro
    CANCER DISCOVERY, 2021, 11 (01) : 17 - 19
  • [43] Post-COVID-19 Tumor Microenvironment Features and AI-Based Evaluation in KRAS-Mutant NSCLC
    Huang, Z.
    Li, L.
    Wang, S.
    Peng, Z.
    Jia, Y.
    Zhang, J.
    He, Q.
    Zeng, S.
    Yang, B.
    He, Y.
    Guan, T.
    Li, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S163 - S164
  • [44] Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
    Allemann, Anna T.
    Gautschi, Oliver
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1328 - 1331
  • [45] KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
    Naidoo, Jarushka
    Drilon, Alexander
    LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 155 - 178
  • [46] Development of siRNA Payloads to Target KRAS-Mutant Cancer
    Yuan, Tina L.
    Fellmann, Christof
    Lee, Chih-Shia
    Ritchie, Cayde D.
    Thapar, Vishal
    Lee, Liam G.
    Hsu, Dennis J.
    Grace, Danielle
    Carver, Joseph O.
    Zuber, Johannes
    Luo, Ji
    McCormick, Frank
    Lowe, Scott W.
    CANCER DISCOVERY, 2014, 4 (10) : 1182 - 1197
  • [47] EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC
    Gaudreau, P.
    Peng, D.
    Rodriguez, B.
    Fradette, J.
    Gibson, L.
    Della Corte, C.
    Sen, T.
    Kundu, S.
    Chen, L.
    Wargo, J.
    Gibbons, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S449 - S450
  • [48] KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
    Rosell, Rafael
    Jantus-Lewintre, Eloisa
    Cao, Peng
    Cai, Xueting
    Xing, Baojuan
    Ito, Masaoki
    Gomez-Vazquez, Jose Luis
    Marco-Jordan, Mireia
    Calabuig-Farinas, Silvia
    Cardona, Andres Felipe
    Codony-Servat, Jordi
    Gonzalez, Jessica
    Valencia-Clua, Kevin
    Aguilar, Andres
    Pedraz-Valdunciel, Carlos
    Dantes, Zahra
    Jain, Anisha
    Chandan, S.
    Molina-Vila, Miguel Angel
    Arrieta, Oscar
    Ferrero, Macarena
    Camps, Carlos
    Gonzalez-Cao, Maria
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [49] Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers
    Klomp, Jennifer E.
    Klomp, Jeff A.
    Diehl, Nathaniel J.
    Edwards, Cole A.
    Drizyte-Miller, Kristina
    Hibshman, Priya S.
    Yang, Runying
    Morales, Alexis J.
    Taylor, Khalilah E.
    Pierobon, Mariaelena
    Petricoin, Emanuel F., III
    Jared, Johnson L.
    Huntsman, Emily M.
    Yaron, Tomer M.
    Vaha-Koskela, Markus
    Herring, Laura E.
    Prevatte, Alex W.
    Barker, Natalie K.
    Graves, Lee M.
    Krister, Wennerberg
    Cantley, Lewis C.
    Christensen, James G.
    Cox, Adrienne D.
    Der, Channing J.
    Stalnecker, Clint A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [50] Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer
    Cox, Adrienne D.
    Goodwin, Craig M.
    Bryant, Kirsten L.
    Dagliyan, Irem
    George, Samuel D.
    Lucas, Kelly E.
    Gautam, Prson
    Wennerberg, Krister
    Der, Channing J.
    CANCER RESEARCH, 2018, 78 (13)
12345